Tonix to develop TNX-102 SL for long Covid treatment
In the third quarter of this year, Tonix will discuss Phase II trial design to assess the drug for long Covid with the US FDA.
Clinical Trials
Pfizer’s tofacitinib lowers mortality in Covid-19 pneumonia trial in Brazil
By day 28, subjects receiving tofacitinib had an 18.1% reduction in the cumulative occurrence of...
Umoja Biopharma raises $210m to develop cancer treatments
The funds will also be used to set up internal manufacturing capabilities to clinically develop...
NRx Pharmaceuticals’ Zyesami yields positive data in EAP for Covid-19
Participants who received at least one dose of Zyesami along with intensive care were alive...
HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science...
Humanigen starts rolling submission for Covid-19 drug in the UK
Humanigen, which previously sought EUA from the US FDA for lenzilumab to treat Covid-19, is seeking marketing approval by the MHRA for the drug.
Ocugen to seek full approval for Bharat Biotech’s Covaxin in the US
Ocugen has exclusive rights to commercialise Covaxin in Canada and is in discussions to obtain potential regulatory authorisation.
Big data and AI are likely to lead emerging technology investments: Survey
With digital transformation gradually picking up pace, the pharmaceutical industry has witnessed an increase in investment in emerging technologies.
Indivior and Aelis enter $130m deal for cannabis addiction therapy
In the initial stage, Indivior will pay $30m to Aelis to secure an exclusive global option for AEF0117.
Strong leadership dominates as key factor for digital transformation across geographies
The pharmaceutical industry believes that the top management of a company plays a crucial role in digital transformation.
Trial that pits Covid-19 monoclonal antibodies to weigh efficacy signals recruits 1,500 participants, with an interim analysis expected shortly
An investigator-led Phase III trial comparing authorised monoclonal antibodies (mAbs) from Eli Lilly and Regeneron Pharmaceuticals to treat Covid-19 has recruited approximately 1,500 participants to date, said investigator Dr David Huang, professor of Critical Care...
